Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer Aβ species, which are more prone to aggregation [28]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“and, consequently, could be more pathogenic than shorter Aβ species”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [8]
In the citing paper
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer's disease (AD) (Haass and Selkoe, 2007).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Haass and Selkoe, 2007
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These and other findings led to the formal proposal of a hypothesis of disease in which excessive Aβ accumulation and deposition could trigger a complex downstream cascade that resulted in the symptoms of A”
ResultRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“In a similar manner, breakthrough discoveries of causative genes allowed the subsequent identification of aggregation-prone proteins in disorders such as amyotrophic lateral sclerosis (ALS”
ResultUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“More recently, TDP43 was found to be deposited in tau- and synuclein-negative inclusions in a disorder designated as frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) as well as in AL”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Shortly thereafter, a distinct APP missense mutation was found in a family with early-onset A”
Background
Cited by
Items 401–500 of 1,119
Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease
Hayne, D. J., Lim, S., & Donnelly, P. S. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00026a · Cited by 174
Udan, M. L. D., Ajit, D., Crouse, N. R., & Nichols, M. R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05001.x · Cited by 174
Scott, J. D., Li, S. W., Brunskill, A. P. J., Chen, X., Cox, K., Cumming, J. N., Forman, M., Gilbert, E. J., Hodgson, R. A., Hyde, L. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00307 · Cited by 174
Young microglia restore amyloid plaque clearance of aged microglia
Daria, A., Colombo, A., Llovera, G., Hampel, H., Willem, M., Liesz, A., Haass, C., & Tahirovic, S. (2017) · The EMBO Journal · doi:10.15252/embj.201694591 · Cited by 174
“As soluble A b species have been strongly implicated in synaptic dysfunction in AD, reducing their levels may indeed be beneficial for cognition (Haass & Selkoe, 2007; Koffie et al , 2009).”
Self-citationCurcumin and neurodegenerative diseases
Monroy, A., Lithgow, G. J., & Alavez, S. (2013) · BioFactors · doi:10.1002/biof.1063 · Cited by 172
“Especially under neurodegenerative conditions, the aggregation of aberrant forms of specific proteins such as a-synuclein (Parkinson’s disease, PD) [17], b-amyloid (Alzheimer’s disease, AD) [18], and huntingtin (Huntington’s disease, HD) [19] may contribute to the onset and/or progression of the disease.”
BackgroundSupersaturation is a major driving force for protein aggregation in neurodegenerative diseases
Ciryam, P., Kundra, R., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.004 · Cited by 174
Critical aggregation concentration for the formation of early Amyloid-β (1–42) oligomers
Novo, M., Freire, S., & Al-Soufi, W. (2018) · Scientific Reports · doi:10.1038/s41598-018-19961-3 · Cited by 173
Wang, J., Fan, Y., Tan, Y., Zhao, X., Zhang, Y., Cheng, C., & Yang, M. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b15452 · Cited by 173
ADF/Cofilin-Actin Rods in Neurodegenerative Diseases
Bamburg, J. R., Bernstein, B. W., Davis, R. C., Flynn, K. C., Goldsbury, C., Jensen, J. R., Maloney, M. T., Marsden, I. T., Minamide, L. S., Pak, C. W., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791050902 · Cited by 173
“Alzheimer Disease (AD) is diagnosed post mortem where the classical pathological hallmarks are extracellular plaques containing amyloid beta (Aβ) peptides [1] and intraneuronal neurofibrillary tangles of the hyperphosphorylated microtubule-associated protein tau [2].”
BackgroundJan, A., Adolfsson, O., Allaman, I., Buccarello, A.-L., Magistretti, P. J., Pfeifer, A., Muhs, A., & Lashuel, H. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172411 · Cited by 173
Bentmann, E., Haass, C., & Dormann, D. (2013) · The FEBS Journal · doi:10.1111/febs.12287 · Cited by 173
Self-citationCu(II) Affinity for the Alzheimer’s Peptide: Tyrosine Fluorescence Studies Revisited
Alies, B., Renaglia, E., Rózga, M., Bal, W., Faller, P., & Hureau, C. (2013) · Analytical Chemistry · doi:10.1021/ac302629u · Cited by 171
Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease
Heller, G. T., Aprile, F. A., Michaels, T. C. T., Limbocker, R., Perni, M., Ruggeri, F. S., Mannini, B., Löhr, T., Bonomi, M., Camilloni, C., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb5924 · Cited by 168
“The fact that the oligomers appear to be the most toxic species formed during the aggregation process (5, 6), however, suggests that therapeutic strategies targeting Aβ aggregation should not primarily aim at inhibiting fibril formation per se, but rather doing so in a manner that specifically reduces the generation o…”
BackgroundThe Amyloid Phenomenon and Its Significance in Biology and Medicine
Dobson, C. M., Knowles, T. P. J., & Vendruscolo, M. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033878 · Cited by 173
“The presence of amyloid deposits in a range of diseases has been known for many years and the link between this phenomenon and the various pathologies has been the subject of much debate (Caughey and Lansbury 2003; Haass and Selkoe 2007; Jack et al. 2018).”
BackgroundThe Role of Mammalian Sirtuins in the Regulation of Metabolism, Aging, and Longevity
Satoh, A., Stein, L., & Imai, S. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-21631-2_7 · Cited by 172
“5.2 SIRT1, AD, and Other Age-Associated Neurological Disorders AD is chronic neurodegenerative disorder leading to synaptic dysfunction and neuronal cell loss (Haass and Selkoe 2007).”
BackgroundInfluentialHu, N.-W., Klyubin, I., Anwyl, R., & Rowan, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908083106 · Cited by 171
Cinnamon extract inhibits tau aggregation associated with Alzheimer’s disease in vitro
Peterson, D. W., George, R. C., Scaramozzino, F., LaPointe, N. E., Anderson, R. A., Graves, D. J., & Lew, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1083 · Cited by 171
Chaperone-dependent amyloid assembly protects cells from prion toxicity
Douglas, P. M., Treusch, S., Ren, H.-Y., Halfmann, R., Duennwald, M. L., Lindquist, S., & Cyr, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802593105 · Cited by 171
“Amyloid deposits in the brain are a hallmark of protein conformational disease, but often there is only a poor correlation between the detection of amyloid fibrils and other markers of neurodegeneration (5).”
BackgroundKaminski Schierle, G. S., van de Linde, S., Erdelyi, M., Esbjörner, E. K., Klein, T., Rees, E., Bertoncini, C. W., Dobson, C. M., Sauer, M., & Kaminski, C. F. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201651w · Cited by 171
Amyloid beta mediates memory formation
Garcia-Osta, A., & Alberini, C. M. (2009) · Learning & Memory · doi:10.1101/lm.1310209 · Cited by 171
“Indeed, a variety of studies have indicated that elevation and accumulation of Ab levels result in cognitive dysfunction, including memory deficits (Haass and Selkoe 2007).”
Role of α‐synuclein penetration into the membrane in the mechanisms of oligomer pore formation
Tsigelny, I. F., Sharikov, Y., Wrasidlo, W., Gonzalez, T., Desplats, P. A., Crews, L., Spencer, B., & Masliah, E. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08489.x · Cited by 170
Shankaran, S. S., Capell, A., Hruscha, A. T., Fellerer, K., Neumann, M., Schmid, B., & Haass, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705115200 · Cited by 170
Self-citationRemondelli, P., & Renna, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00187 · Cited by 169
“Protein unfolding can be considered the initial event endorsing neurodegenerative diseases (Selkoe, 2003; Haass and Selkoe, 2007; Uversky, 2007; Makioka et al., 2010; Lindquist and Kelly, 2011; Martin et al., 2011; Roussel et al., 2013; Hetz and Mollereau, 2014; Valastyan and Lindquist, 2014) that…”
BackgroundInsight into Amyloid Structure Using Chemical Probes
Reinke, A. A., & Gestwicki, J. E. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01110.x · Cited by 169
Neurodegenerative processes in Huntington's disease
Bano, D., Zanetti, F., Mende, Y., & Nicotera, P. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.112 · Cited by 169
Amyloid formation as a protein phase transition
Michaels, T. C. T., Qian, D., Šarić, A., Vendruscolo, M., Linse, S., & Knowles, T. P. J. (2023) · Nature Reviews Physics · doi:10.1038/s42254-023-00598-9 · Cited by 167
Hu, Y., Xu, P., Pigino, G., Brady, S. T., Larson, J., & Lazarov, O. (2010) · The FASEB Journal · doi:10.1096/fj.09-136945 · Cited by 168
“highly neurotoxic (7), it is critical to determine whether experience in a complex environment would modulate these forms specifically.”
BackgroundRecent progress in understanding Alzheimer's β-amyloid structures
Fändrich, M., Schmidt, M., & Grigorieff, N. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.02.002 · Cited by 168
“In vitro Aβ fibrillation reactions involve a range of different on- or off-pathway intermediates, and it is thought that similar structures, such as oligomers or protofibrils, can become stabilized also during disease [2,6,7,52].”
BackgroundFinder, V. H., Vodopivec, I., Nitsch, R. M., & Glockshuber, R. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.12.016 · Cited by 168
“The toxicity of Aβ peptides is generally attributed to low-molecular-weight assembly intermediates of Aβ.(40) As recombinant Aβ1–42 showed significantly enhanced neurotoxicity compared to the synthetic peptide towards cultured primary neurons in vitro and P301L tau transgenic mice in vivo, a higher concentration or mo…”
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168
“It has been established that soluble forms of Aβ, but not fibrils (Kayed et al., 2003; Baglioni et al., 2006; Haass and Selkoe, 2007; Shankar et al., 2007; Walsh and Selkoe, 2007), correlate with the onset of the disease only in the presence of tau, suggesting that the latter mediates Aβ toxicity…”
BackgroundVolianskis, A., Køstner, R., Mølgaard, M., Hass, S., & Jensen, M. S. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.005 · Cited by 166
Bayer, T. A., & Wirths, O. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1287-x · Cited by 165
“Antibodies targeting plaques could even have a noxious effect by solubilizing fibrillar and innocuous Aβ [5, 32].”
A Drosophila Model for Amyotrophic Lateral Sclerosis Reveals Motor Neuron Damage by Human SOD1
Watson, M. R., Lagow, R. D., Xu, K., Zhang, B., & Bonini, N. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804817200 · Cited by 163
The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
Badiola, N., Alcalde, V., Pujol, A., Münter, L.-M., Multhaup, G., Lleó, A., Coma, M., Soler-López, M., & Aloy, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058837 · Cited by 165
“There is data showing that soluble forms of Ab correlate more closely with dementia severity than fibrillar Ab [9,10,11,12] and that Ab oligomers alter dendritic spine density and affect hippocampal synaptic plasticity in vivo [13,14,15,16,17].”
BackgroundDesigning Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's β-Amyloid Peptide
Austen, B. M., Paleologou, K. E., Ali, S. A. E., Qureshi, M. M., Allsop, D., & El-Agnaf, O. M. A. (2008) · Biochemistry · doi:10.1021/bi701415b · Cited by 166
Dá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Tewari, D., Sharma, G., Kabir, M. T., Barreto, G. E., Bin-Jumah, M. N., Perveen, A., Abdel-Daim, M. M., & Ashraf, G. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01929-y · Cited by 164
Tai, L. M., Ghura, S., Koster, K. P., Liakaite, V., Maienschein‐Cline, M., Kanabar, P., Collins, N., Ben‐Aissa, M., Lei, A. Z., Bahroos, N., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13072 · Cited by 165
“…et al. 1999; McLean et al. 1999; Wang et al. 1999), specifically soluble oAb (Kuo et al. 1996; Tomic et al. 2009; Jin et al. 2011; Selkoe 2011; Hayden & Teplow 2013; Teplow 2013; Sebollela et al. 2014), rather than insoluble Ab (Hardy 2006; Haass & Selkoe 2007) may be the proximal neurotoxin in AD.”
Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165
“The amyloid hypothesis has been revised, as plaque burden does not correlate with the dementia that is characteristic of AD (12, 13).”
BackgroundSynaptic Change in the Posterior Cingulate Gyrus in the Progression of Alzheimer's Disease
Scheff, S. W., Price, D. A., Ansari, M. A., Roberts, K. N., Schmitt, F. A., Ikonomovic, M. D., & Mufson, E. J. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-141518 · Cited by 165
“Numerous studies have focused on levels of both soluble and insoluble A as possible mechanisms underlying both synapse loss and dementia in AD [7, 103].”
Page, R. M., Baumann, K., Tomioka, M., Pérez-Revuelta, B. I., Fukumori, A., Jacobsen, H., Flohr, A., Luebbers, T., Ozmen, L., Steiner, H., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708754200 · Cited by 165
Self-citationNano-biosensors to detect beta-amyloid for Alzheimer's disease management
Kaushik, A., Jayant, R. D., Tiwari, S., Vashist, A., & Nair, M. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.01.065 · Cited by 165
“Hypothesis of β-A to monitor Alzheimer’s Diseases The role of β-A peptide for AD monitoring has been investigated and well-accepted (Claeysen et al. 2015; Haass and Selkoe 2007; LaFerla et al. 2007).”
BackgroundBiscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164
Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody
Youmans, K. L., Tai, L. M., Kanekiyo, T., Stine Jr, W. B., Michon, S.-C., Nwabuisi-Heath, E., Manelli, A. M., Fu, Y., Riordan, S., Eimer, W. A., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-8 · Cited by 164
“toxicity in vitro and in vivo (reviewed [41,44,45]).”
BackgroundThe Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration
Perri, E. R., Thomas, C. J., Parakh, S., Spencer, D. M., & Atkin, J. D. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00080 · Cited by 164
Taylor, M., Moore, S., Mayes, J., Parkin, E., Beeg, M., Canovi, M., Gobbi, M., Mann, D. M. A., & Allsop, D. (2010) · Biochemistry · doi:10.1021/bi100144m · Cited by 160
Fernando, W. M. A. D. B., Martins, I. J., Morici, M., Bharadwaj, P., Rainey-Smith, S. R., Lim, W. L. F., & Martins, R. N. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190120 · Cited by 164
“Elevated levels of A (cid:2) are believed to contribute to the cognitive impairments associated with AD [2, 3] by causing structural and functional changes to neurons [4, 5].”
Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimer’s Disease
Kumar, R., Chaterjee, P., Sharma, P. K., Singh, A. K., Gupta, A., Gill, K., Tripathi, M., Dey, A. B., & Dey, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061560 · Cited by 162
“In case of AD the down regulation of SIRT1 reduces the expression of asecretase and as a result the accumulation of pathogenic Ab peptide formed by b and c secretase [16].”
Backgroundγ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer’s Drugs
Oehlrich, D., Berthelot, D. J.-C., & Gijsen, H. J. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101168r · Cited by 161
Amyloid‐β oligomers set fire to inflammasomes and induce Alzheimer's pathology
Salminen, A., Ojala, J., Suuronen, T., Kaarniranta, K., & Kauppinen, A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00496.x · Cited by 162
Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease
Hanzel, C. E., Pichet-Binette, A., Pimentel, L. S. B., Iulita, M. F., Allard, S., Ducatenzeiler, A., Do Carmo, S., & Cuello, A. C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.026 · Cited by 161
“At advanced stages of the pathology, in the presence of extracellular amyloid plaques, inflammation is an invariable component of the disease and might contribute to CNS dysfunction, injury, and ultimately loss of neurons (Haass and Selkoe, 2007).”
BackgroundDeregulation of purine metabolism in Alzheimer's disease
Ansoleaga, B., Jové, M., Schlüter, A., Garcia-Esparcia, P., Moreno, J., Pujol, A., Pamplona, R., Portero-Otín, M., & Ferrer, I. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.004 · Cited by 159
“…neurofibrillary tangles composed of abnormally phosphorylated, and conformed and truncated tau, and senile plaques with a core of the altered cleavage of amyloid precursor protein leading to the deposition of b-amyloid (Duyckaerts and Dickson, 2011; Haass and Selkoe, 2007; Lowe et al., 2008).”
BackgroundFujita, K., Motoki, K., Tagawa, K., Chen, X., Hama, H., Nakajima, K., Homma, H., Tamura, T., Watanabe, H., Katsuno, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31895 · Cited by 160
Bhattarai, P., Thomas, A. K., Cosacak, M. I., Papadimitriou, C., Mashkaryan, V., Froc, C., Reinhardt, S., Kurth, T., Dahl, A., Zhang, Y., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.075 · Cited by 151
Santos, R. X., Correia, S. C., Wang, X., Perry, G., Smith, M. A., Moreira, P. I., & Zhu, X. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100666 · Cited by 160
“: +351 239480012; Fax: +351 239480034; E-mail: venta@ci.uc.pt or pismoreira@gmail.com.”
Distinct thermodynamic signatures of oligomer generation in the aggregation of the amyloid-β peptide
Cohen, S. I. A., Cukalevski, R., Michaels, T. C. T., Šarić, A., Törnquist, M., Vendruscolo, M., Dobson, C. M., Buell, A. K., Knowles, T. P. J., & Linse, S. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0023-x · Cited by 160
Darnell, G., Orgel, J. P. R. O., Pahl, R., & Meredith, S. C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.09.023 · Cited by 160
Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 159
“, 2003) represent the most toxic forms of the peptide causing impaired synaptic and neuronal functions (Haass and Selkoe, 2007; Walsh and Selkoe, 2007).”
BackgroundRas and Rap Signaling in Synaptic Plasticity and Mental Disorders
Stornetta, R. L., & Zhu, J. J. (2011) · The Neuroscientist · doi:10.1177/1073858410365562 · Cited by 158
Biological activity of peptides purified from fish skin hydrolysates
Abuine, R., Rathnayake, A. U., & Byun, H.-G. (2019) · Fisheries and Aquatic Sciences · doi:10.1186/s41240-019-0125-4 · Cited by 159
Lord, A., Gumucio, A., Englund, H., Sehlin, D., Sundquist, V. S., Söderberg, L., Möller, C., Gellerfors, P., Lannfelt, L., Pettersson, F. E., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.08.007 · Cited by 158
“Indeed soluble Aβ levels better reflect severity of dementia in AD patients (Lue et al., 1999; McLean et al., 1999), and multiple assemblies of oligomeric Aβ cause synaptic dysfunction and/ormemory impairment ((Haass and Selkoe, 2007) and references therein).”
BackgroundA canine model of human aging and Alzheimer's disease
Head, E. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.016 · Cited by 158
Wu, J. W., Breydo, L., Isas, J. M., Lee, J., Kuznetsov, Y. G., Langen, R., & Glabe, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.069542 · Cited by 158
Wolstenholme, C. H., Hu, H., Ye, S., Funk, B. E., Jain, D., Hsiung, C.-H., Ning, G., Liu, Y., Li, X., & Zhang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07245 · Cited by 158
“Cell Chem Biol 2017, 24 (6), 725–736 e7.”
Metal Ion Physiopathology in Neurodegenerative Disorders
Bolognin, S., Messori, L., & Zatta, P. F. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8102-1 · Cited by 169
Ruggeri, F. S., Adamcik, J., Jeong, J. S., Lashuel, H. A., Mezzenga, R., & Dietler, G. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201409050 · Cited by 157
Monomer-dependent secondary nucleation in amyloid formation
Linse, S. S. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0289-z · Cited by 166
“ity is mainly associated with protein oligomers (Bucciantini et al. 2002; Walsh et al. 2002; Haass and Selkoe 2007).”
BackgroundQosa, H., Batarseh, Y. S., Mohyeldin, M. M., El Sayed, K. A., Keller, J. N., & Kaddoumi, A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00190 · Cited by 156
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
Wilcox, K. C., Lacor, P. N., Pitt, J., & Klein, W. L. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9691-4 · Cited by 155
“instead that plaque load does not dictate the severity of AD (Haass and Selkoe 2007).”
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice
Ledo, J. H., Azevedo, E. P., Clarke, J. R., Ribeiro, F. C., Figueiredo, C. P., Foguel, D., De Felice, F. G., & Ferreira, S. T. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.168 · Cited by 155
Dormann, D., Capell, A., Carlson, A. M., Shankaran, S. S., Rodde, R., Neumann, M., Kremmer, E., Matsuwaki, T., Yamanouchi, K., Nishihara, M., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06211.x · Cited by 156
Self-citationA Hexameric Peptide Barrel as Building Block of Amyloid‐β Protofibrils
Lendel, C., Bjerring, M., Dubnovitsky, A. P., Kelly, R. T., Filippov, A. V., Antzutkin, O. N., Nielsen, N. C., & Härd, T. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201406357 · Cited by 162
Ghag, G., Bhatt, N., Cantu, D. V., Guerrero‐Munoz, M. J., Ellsworth, A., Sengupta, U., & Kayed, R. (2018) · Protein Science · doi:10.1002/pro.3499 · Cited by 154
Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease
Gupta, J., Fatima, M. T., Islam, Z., Khan, R. H., Uversky, V. N., & Salahuddin, P. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.02.156 · Cited by 156
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
Flores-Dorantes, M. T., Díaz-López, Y. E., & Gutiérrez-Aguilar, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00863 · Cited by 156
“Alzheimer disease is characterized by an abnormal accumulation and deposition of β-amyloid peptide on the amyloid plaque (Haass and Selkoe, 2007).”
BackgroundSynaptotoxicity of Alzheimer Beta Amyloid Can Be Explained by Its Membrane Perforating Property
Sepulveda, F. J., Parodi, J., Peoples, R. W., Opazo, C., & Aguayo, L. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011820 · Cited by 154
“Only recent studies have dealt with the action of Ab at concentrations without overt neurotoxicity on synaptic properties [3].”
BackgroundGennarino, V. A., Singh, R. K., White, J. J., De Maio, A., Han, K., Kim, J.-Y., Jafar-Nejad, P., di Ronza, A., Kang, H., Sayegh, L. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.012 · Cited by 155
“In all these diseases, the mutant proteins form insoluble aggregates (Haass and Selkoe, 2007; Klement et al., 1998; Ross and Poirier, 2004; Zoghbi and Orr, 2000).”
BackgroundWong, P. T., Schauerte, J. A., Wisser, K. C., Ding, H., Lee, E. L., Steel, D. G., & Gafni, A. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.060 · Cited by 174
Leuner, K., Müller, W. E., & Reichert, A. S. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8307-4 · Cited by 177
“, synaptic failure, mitochondrial dysfunction, enhanced oxidative stress, neurotransmitter and neurotrophin depletion, inflammation, and apoptosis which is reflected in patients as clinical symptoms such as cognitive deficits [2, 3].”
BackgroundKayed, R., Canto, I., Breydo, L., Rasool, S., Lukacsovich, T., Wu, J., Albay, R., Pensalfini, A., Yeung, S., Head, E., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-57 · Cited by 155
“Indeed, soluble oligomers have been implicated as primary causative agents in many different degenerative diseases where the accumulation of large fibrillar deposits may be either inert or protective (reviewed in [6,7]).”
Yang, D., Wang, C.-E., Zhao, B., Li, W., Ouyang, Z., Liu, Z., Yang, H., Fan, P., O'Neill, A., Gu, W., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq313 · Cited by 155
“These neurodegenerative diseases consist of Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS) and polyglutamine (polyQ) diseases, which are characterized by selective neuronal loss with the accumulation of toxic and misfolded proteins (4,5).”
BackgroundMathematical model on Alzheimer’s disease
Hao, W., & Friedman, A. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0348-2 · Cited by 183
“Equation for AβO The AβO are soluble Aβ oligomers and they can diffuse throughout the brain tissue [49, 50].”
BackgroundCurcumin, Hormesis and the Nervous System
Scuto, M. C., Mancuso, C., Tomasello, B., Ontario, M. L., Cavallaro, A. S., Frasca, F., Maiolino, L., Salinaro, A. T., Calabrese, E. J., & Calabrese, V. (2019) · Nutrients · doi:10.3390/nu11102417 · Cited by 157
Fernández, A., Llacuna, L., Fernández-Checa, J. C., & Colell, A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4909-08.2009 · Cited by 153
“Although AD pathogenesis is still unknown, accumulation or faulty brain clearance of neurotoxic amyloid peptides (A ) is thought to play a key role in AD (Tanzi et al., 2004; Walsh and Selkoe, 2004; Deane and Zlokovic, 2007; Haass and Selkoe, 2007).”
BackgroundReelin signaling antagonizes β-amyloid at the synapse
Durakoglugil, M. S., Chen, Y., White, C. L., Kavalali, E. T., & Herz, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908176106 · Cited by 153
“We have shown that activation of ApoE receptors with their natural ligand Reelin can prevent the impairment of synaptic functions caused by A oligomers, which are present in AD but not in normal non-diseased brain (31).”
BackgroundDementia of the eye: the role of amyloid beta in retinal degeneration
Ratnayaka, J. A., Serpell, L. C., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.100 · Cited by 153
Eckert, A., Hauptmann, S., Scherping, I., Rhein, V., Müller-Spahn, F., Götz, J., & Müller, W. E. (2008) · Neurodegenerative Diseases · doi:10.1159/000113689 · Cited by 153
Synaptic memory mechanisms: Alzheimer's disease amyloid β-peptide-induced dysfunction
Rowan, M. J., Klyubin, I., Wang, Q., Hu, N. W., & Anwyl, R. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351219 · Cited by 152
Zumkehr, J., Rodríguez‐Ortiz, C. J., Cheng, D., Kieu, Z., Wai, T., Hawkins, C., Kilian, J., Lim, S., Medeiros, R., & Kitazawa, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.005 · Cited by 167
“Dementia severity among AD patients correlates well with synaptic loss and oligomeric Ab species and to a lesser extent, with Ab plaques in the brain (Dickson et al., 1992; Haass and Selkoe, 2007; Hardy and Selkoe, 2002; Scheff et al., 2006; Selkoe, 2002; Tomic et al., 2009).”
Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders
Choi, J. G., Kim, S. Y., Jeong, M., & Oh, M. S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.010 · Cited by 165
Taurine and central nervous system disorders
Menzie, J., Pan, C., Prentice, H. M., & Wu, J. (2012) · Amino Acids · doi:10.1007/s00726-012-1382-z · Cited by 166
“…in the ratio of Ab 42 to Ab 40 due to a mutant variant of c-secretase results in extracellular aggregates of the insoluble Ab 42 , which grow into fibrils and eventually b-pleated sheets, as observed in advanced amyloid plaques (Haass and De Strooper 1999; Haass 2004; Haass and Selkoe 2007).”
BackgroundResultInfluentialNutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals
Berti, V., Murray, J., Davies, M., Spector, N., Tsui, W. H., Li, Y., Williams, S., Pirraglia, E., Vallabhajosula, S., McHugh, P., et al. (2015) · The Journal of nutrition, health and aging · doi:10.1007/s12603-014-0534-0 · Cited by 152
“Nonetheless, it is possible that FDG and MRI effects reflect toxic effects of Aβ oligomers, which are known to occur early in AD (55) and which are not currently visible on PET imaging.”
Vitamin A and Alzheimer's disease
Ono, K., & Yamada, M. (2012) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2011.00786.x · Cited by 151
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Hernandez, C., Barrett, A. D. T., Dineley, K., & Kayed, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4989-14.2015 · Cited by 149
“Growing evidence implicates small soluble oligomeric assembles of misfolded amyloids as critical pathogenic species (Haass and Selkoe, 2007; Lasagna-Reeves et al., 2011a; CastilloCarranza et al., 2013a,b).”
BackgroundIdentification of an Aggregation-Prone Structure of Tau
Elbaum-Garfinkle, S., & Rhoades, E. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305206m · Cited by 149
Multiple events lead to dendritic spine loss in triple transgenic Alzheimer’s disease mice
Bittner, T., Fuhrmann, M., Burgold, S., Ochs, S. M., Hoffmann, N., Mitteregger, G., Kretzschmar, H., LaFerla, F. M., & Herms, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015477 · Cited by 149
“soluble forms like monomers and oligomers or insoluble fibrils primarily contributes to AD pathogenesis and in what way remains controversial [10,11].”
Jameson, L. P., Smith, N. W., & Dzyuba, S. V. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300076x · Cited by 158
Sehlin, D., Englund, H., Simu, B., Karlsson, M., Ingelsson, M., Nikolajeff, F., Lannfelt, L., & Pettersson, F. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032014 · Cited by 149
“suggested as a future therapy of AD [37,38,39,40] and therefore, it is important to characterize the soluble Ab pool of i.”
Background
Metadata
- Authors
- Haass, C., & Selkoe, D. J.
- Affiliations
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 101-112
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1980825524
- Cited by
- 4,744
- References
- 135
- Citations by year
- 2026: 135 · 2025: 171 · 2024: 165 · 2023: 170 · 2022: 195 · 2021: 239 · 2020: 273 · 2019: 247 · 2018: 276 · 2017: 290 · 2016: 331 · 2015: 313 · 2014: 285 · 2013: 307 · 2012: 327
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurodegeneration, protein misfolding, protein aggregation, synaptic dysfunction, synaptic plasticity, Parkinson's disease, Huntington's disease, prion disease, neuronal dysfunction
- MeSH terms
- Alzheimer Disease, Cell Membrane, Humans, Memory Disorders, Models, Biological, Nerve Degeneration, Solubility, Synapses, Signal Transduction, Amyloid beta-Peptides, Protein Folding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.